



INVEST IN ONE HEALTH BIOSENSING

AI enabled, ultra-low cost, and pain-free, needle-free - We didn't invent CGM, we just redefined it

onehealthbiosensing.com

New York, NY




Highlights

- 1 A multi-modal AI-enabled health sensing platform designed to revolutionize the \$10bn CGM market
- 2 A low-cost, painless, needle-free solution for >1Bn people with diabetes, pre-diabetes and obesity

- 3 Proprietary silicon micro-needle array technology, 10 years in R&D, protected by >50 issued patents
- 4 Demonstrated performance in >1,500 hrs of onbody clinical data with an estimated MARD of <10
- 5 Bolstered by >60Bn data points and AI capabilities proven to reduce A1C by 1.9% and weight by >10lbs
- 6 Projecting \$250M in revenue two years post launch and >\$1bn five years post launch (not guaranteed)
- 7 Founder and CEO with a proven track record of successful exits and a world class leadership team
- 8 Existing investors include RRE, Box Group, FJ Labs, True Ventures, First Round Capital, and others

Featured Investors



Craig Kanarick 
Syndicate Lead

Follow

Invested \$5,000 

Craig is the CEO of New York Cruise Lines, a marine-based sightseeing, entertainment and transportation business based in NYC.

“The market for CGM is expected to be explosive and expand rapidly as people start to monitor their blood glucose to manage diabetes, weight, and health. The AI-enabled, ultra-low cost, pain free, flexible One Health CGM is exactly what the market and payers want to keep people healthy. Today the 2 existing CGM players (Abbott and Dexcom) have products engineered for intensive insulin users and are high cost to payers. With One Health, people with Type 2 diabetes not on insulin, people on GLP-

1s, people trying to lose weight, and people interested in monitoring their health will have affordable access to CGM. This is a winning team, a winning technology, a winning market opportunity, and has the potential to impact millions of lives.”



Other investors include [RRE Ventures](#), [First Round Capital](#), [M. Night Shyamalan](#), [Tony Fadell](#)

Our Team



Jeff Dachis Founder and CEO

A proven track record of successful entrepreneurship and disruptive innovation and over a decade of experience in digital design and the diabetes industry



Jon Brilliant CFO

Proven track record developing and launching diabetes devices



Dan Goldner EVP Research & Development

Proven expertise in data science, machine learning, and AI



Brian Kemper EVP Product & Programs

15+ years in medical devices and digital solutions

One Health: Make sense of your health



one health

Make Sense of Your Health

one health

The Opportunity

Next Generation Health Sensing Experience
designed to revolutionize the CGM market with a device purpose built for people with Type 2 diabetes, 95% of whom are unserved by CGM today

Enabled By AI Proven to Improve Health Outcomes
made possible >60 billion real-time, contextual data points fueling first-to-market predictions

Made Possible with Proprietary Technology
integrating a micro-needle based sensing platform with personalized AI to deliver continuous sensing and continuous insight

Unlocking Broad Payor Coverage & Reimbursement
with a low cost daily disposable sensor that reduces starting price point for CGMs by up to 90%


Maximizing Adoption and Winning in Type 2 Diabetes
with a low cost, no commitment CGM experience purpose built to deliver access, affordability, and outcomes for people with Type 2 Diabetes

Device shown is under development and subject to FDA clearance or approval. Future Projections Not Guaranteed



2 | PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.

A Next Generation Health Sensing Experience

- Durable Applicator
- Durable Battery + Transmitter



Built On A Micro-Needle Based Platform with Multi-Modal Sensing Capabilities



The CGM Market Has Experienced Explosive Growth Over the Past 10 Years

There were >8M CGM users globally generating ~\$10Bn in CGM revenue


The market is dominated by two large players with similar 10-14 day

The existing CGM paradigm leaves >90% of people with T2D unserved

in 2023


devices at comparable price points

and is ripe for disruption



FreeStyle Libre 2 5.5M Users \$1.4Bn Q4'23 Revenue

DEXCOM 2.3M Users \$1Bn Q4'23 Revenue



6 PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSCIENCE INC.

one health

Meet Jim...

Jim has Type 2 Diabetes and does not want to start using insulin. He is willing to adjust his lifestyle to get his A1C under control but needs some help getting started.

His doctor suggests starting on a CGM. This will help Jim understand what impacts his blood sugar and make the right decisions to improve his health.

Jim's insurance does not reimburse for CGM. He wants to know how much will this cost?



High Costs Make CGM Uncovered and Unaffordable For Most People with Type 2 Diabetes



The Numbers¹

12 Applicators
12 Batteries
12 Bluetooth Transmitters
12+ Sensors

Day 1 Cost = \$70

Lowest Annual Cost¹ = \$840

✗ Not reimbursed by insurance
✗ Not affordable out-of-pocket

¹: Assumes at least one sensor a month.

8 PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSCIENCE INC.

one health

to get his A1C under control but needs some help getting started.



His doctor suggests starting on a CGM. This will help Jim understand what impacts his blood sugar and make the right decisions to improve his health.

Jim's insurance does not reimburse for CGM. He wants to know how much will this cost?



High Costs Make CGM Uncovered and Unaffordable For Most People with Type 2 Diabetes

Fully disposable every 14 days. Sensor price includes the fixed costs of a new applicator, battery, and transmitter for each wear

The Numbers¹
12 Applicators
12 Batteries
12 Bluetooth Transmitters
12+ Sensors

Day 1 Cost = \$70

Lowest Annual Cost¹ = \$840
X Not reimbursed by insurance
X Not affordable out-of-pocket

1. Assumes at least one sensor a month

8 PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSCIENCE LLC

one health

one health

1. Assumes at least one sensor a month

10 PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSCIENCE LLC

one health

✓ Reimbursable for all patient segments
✓ Affordable at \$5 a day

When One Health is manufactured, we predict it will be the lowest cost CGM on the market

Future projections are not guaranteed.

One Health is the Cost Effective and Reimbursable CGM Choice

	Diagnosis: 3 CGM days per month 1.2M people per year (U.S.)	GLP-1 Companion: 5 CGM days per month 15.5M people (U.S.) ¹	T2 Uncontrolled: 7 CGM days per month	Insulin-Management: 24/7/365 CGM ~5M people (U.S.) ¹
one health \$5 per sensor No commitment	\$15 / month	\$25 / month	\$35 / month	\$1,825 / year
	▲ Daily wear flexibility supports a variable cost model, enabling payors to find a reimbursable use case for each T2 patient segment			
dexcom \$60 per sensor	▼ High fixed costs make broad T2 reimbursement financially untenable for most payors			
	\$60 / month	\$60 / month	\$60 / month	\$7,190 / year

10 day commitment

FreeStyle Libre2

\$70 per sensor

14 day commitment

\$70 / month

\$70 / month

\$70 / month

\$1,825 / year

1. KIP Health Tracking Ltd (April 29-May 1, 2024)

2. PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH SENSING INC.

one health

Immense data wealth and AI capabilities to inform action and improve outcomes, enabling the class effect of CGM even on days when a sensor is not being worn

PATTERN

Trend Sensitive

12am - 4am

Everyday

+20 mg/dL

145

70

12 AM

2

4

6

8

10

12 PM

2

4

6

8

10

12 AM

Everyday between 12 am and 4 am, Your glucose tends to be 20 mg/dL higher compared to your daily average glucose of 133 mg/dL.

What can I do about it?

Proven Results³

35 min

Additional activity per week¹

20g

Fewer carbs per meal¹

1.9%

Reduction in eA1c in 3 months^{1,2}

4.7x

lower risk of depression³

21 mm Hg

reduction in systolic blood pressure⁴

10.4lbs

reduction in weight⁵

1. Odean CY, Heyman M, Hudson R, van Briel JR, Rodbard D, Datta J. The One Drop Mobile App with iDapp: Changing Insulin Regimen and Self-care. Diabetes (ADA Abstract Book). 2017;20(Suppl 1):A728.

2. Odean CY, Heyman M, and Datta J. The One Drop Mobile App and Experts Program: Evidence-based and Improves Blood Glucose. Ann Behav Med (Suppl 1):33-50(2017).

3. Sato J, Gohara T, Nagai H, and others. Odean CY, Datta J. One Drop Digital App and Coaching: Improves Diabetes Risk, Glycemic Control and Psychological Well-being in People with Type 2 Diabetes. Circulation 2022;144:A5952.

4. Sato J, Hayashi T, Pongir K, Rintz A, Ito A, Sanchez-Medina R, Nagai H, Gohara T, Datta J. One Drop's Multiplication Program is Associated with Blood Pressure Reduction in Employees with High Blood Pressure and Maintenance for Employees with Blood Pressure in Range. Circulation 2022;144:A7470.

5. Odean CY, Heyman M, Heyman M, Hudson R, Rodbard D, Datta J. One Drop improves A1c among people with Type 2 Diabetes. Ann Behav Med. 2019;20(Suppl 1):556.

one health

FreeStyle Libre2

one health

DEXCOM

Pain-free, needle free application breaks down barriers to adoption and adherence

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

Multi-modal sensing capabilities with electrical and optical sensors integrated into transmitter

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

A design-forward consumer grade experience that feels anything but clinical

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

Reduced carbon footprint with reusable elements and limited use of single-use plastics

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

1. PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH SENSING INC.

one health

Uniquely enabled by

including proprietary

and AI fueled by

Uniquely enabled by
set of capabilities

including proprietary
micro-needle based
sensing technology

and AI fueled by
unprecedented data
wealth

Patented Micro-Needle Based Sensing Platform Ten Years in the Making

One Health's proprietary micro-needle design and application is an engineering breakthrough that makes micro-needle based sensing possible

Proprietary dicing technique delivers clean, durable needle shape

Silicon oxide insulation reduces interference for accurate sensing

Controlled application ensures effective contact with minimal adverse events

Polymers specifically chosen to provide selectivity

Wafer-scale manufacture provides path for continued cost reduction

one health

Unparalleled Cost Leadership Enabled by Unique Engineering Capabilities

Disposable micro-needle sensors built on silicon wafers enable continued COGs reduction



Automation
13% improvement in yield



Increase Wafer Size
1.9x increase in die per wafer going from a 6 to 8 inch wafer.



Decrease Array Size
2.5x increase in die per wafer when decreasing from a 5x5 to 3x3 array

Durable components can be reused across multiple wears

Includes the battery and bluetooth transmitter as well as optical and electronic sensing components

Reusable for two years, allowing the cost to be amortized over many wears

Cost-effective scaling with minimal capital expenditure requirements

Micro-needle sensors built on silicon wafers allow us to leverage existing silicon wafer manufacturing infrastructure

Minimal capital and operating expenses required

Chemistry and biological materials are integrated onto semiconductor chip manufacturing to rapidly produce low-cost sensors

one health

Personalized AI Powered By Unprecedented Biometric Data Wealth

Over 60bn real-time,



AI Blood




AI Blood




AI Weight



AI BGM Outcomes



One Health CGM Functionality Has Been Successfully Demonstrated in Clinic



*Actual MARDs will be based on versus blood draws and final prospect algorithm.

18 PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.

1,656 hours of on-body clinical data collected to date

198,720 data points from 69 wears on 39 people under IRB-approved protocol

Estimated MARD < 10

Based on correlation with 7,131 reference CGM data points.^a

24-hour wear confirmed

Successful skin adhesion, data transmission, and battery life

Demonstrated safety & tolerability

Zero instances of serious adverse events or instances of papules, edema or vesicular eruptions

510(k) pathway validated by FDA

Regulatory pathway and predicate device validated by the FDA through the pre-submission process

*FDA Clearance Not Guaranteed

one health

One Health Intellectual Property

54 Issued Patents 41 Pending or Allowed Applications¹ 7 Licensed Applications³

Wearable Sensing Systems

Wearable Sensors, Applicators, Software

US10,595,754 (B008.US00); US11,172,851² (B008.US02); US11,357,430 (B008.US03); US11,817,222 (B008.US07); US11,291,390 (B002.US08); US11,772,866 (B002.US09); US11,772,885 (B005.US06); US17,236,753 (B016.US03); CA3,180,804 (B016.CA00); EP217,279,611 (B016.EP00); US16,791,518 (B008.US01); US17,728,893 (B008.US06); US18,130,873 (B008.US08); US17,647,530 (B021.US01); US17,590,673 (B002.US10); US17,590,689 (B002.US11); US17,681,689 (B002.US12); 17/681,681 (B002.US13).

Cloud Platform

US17,156,620 (B002.US08); US17,236,753 (B016.US03); CA3,180,804 (B016.CA00); EP217,279,611 (B016.EP00).

Designs

Sensor Device, Applicator, Charging Station

US 8,624,034 (B01.US00); US 8,620,988 (B02.US00); EP 8,752,242.1.11 (B02.3.B025.EU00); AU2021165,014 (B023.AU00); AU2021165,005 (B024.AU00); AU2021165,006 (B025.AU00); GB8,708,857 - GB8,708,859 (B023.GB00-GB02); GB8,708,860 - GB8,708,863 (B024.GB00-GB03); GB8,708,864 - GB8,708,867 (B025.GB00-GB03); B023.JP00 - B023.JP02; B024.JP00 - B024.JP02; B025.JP00-B025.JP02; KR20-2021-49924 to KR20-2021-49926 (B023.KR00 - B025.KR03); US2018,882 (B023.US00); US29/891,202 (B023.US01); US29/779,913 (B024.US00); US29/779,914 (B025.US00); CA, CN (B023); CN20213069203.5.7 (B024.CN00); CN20213069203.2 (B025.CN00).

1. Use of February 2, 2028


2. Adapted in filing more than once due to scope of application or issued patent

3. Licensed from Informa Data Systems Inc. (a/b/a One Drop)

18 PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.




Clear Path to FDA Submission and Launch in Two Years



Future projections are not guaranteed

Use of Proceeds Will Enable One Health to Reach A Meaningful Value Inflection Point



Future projections are not guaranteed

Launching in 2026 with \$250M in Revenue 2 Years Post Launch *Future Projections Not Guaranteed

2028 **\$250M**

230K U.S. Users
3% Share of U.S. Market
45% Gross Margin

2031 **\$1Bn**

980K U.S. Users
9% Share of U.S. Market
60% Gross Margin

A Highly Differentiated Positioning Enables Rapid Uptake

Achieving T2D adoption by enabling a flexible pricing structure and reimbursable cost profile.

Delivering Continued Gross Margin Expansion

Scaling efficiencies across multiple levers including automation, scale, silicon wafer size, and size of micro-needle array.

2026 2027 2028 2029 2030 2031

one health

A Seasoned Leadership Team With Deep Experience and Proven Success and Abilities to Execute



Jeff Dachis, MA
Chairman, CEO and Founder

A Track Record of Successful Entrepreneurship and Disruptive Innovation

razorfish

- Co-Founder and CEO
- \$55M IPO
- \$6B sale to Microsoft
- \$2B annual revenue today



- Chairman, CEO and Founder
- >\$100M raised
- >1.5M registered users
- >\$50M revenue in 2021



Jon Brilliant, BS, JD
CFO

Proven track record developing and launching diabetes devices



Dan Goldner, M.Ed., Ph.D

Research & Development

Proven expertise in data science, machine learning, and AI



Brian Kemper

Product & Programs

15+ years in medical devices and digital solutions



one health

The Opportunity

AI -Enabled CGM Purpose Built to Win in Type 2 Diabetes

Enabled by Proprietary Technology

Integrating a micro-needle based sensing platform with personalized AI proven to improve health outcomes

High Growth With Favorable Economics

projecting \$250M of revenue in 2028 and a clear path to continued margin expansion

Designed To Unlock Payor Coverage

eliminating existing barriers to access with the lowest cost profile and greatest use case flexibility

Future Proofed Platform Technology

poised to extend rapidly beyond glucose and beyond diabetes.

Near-Term Catalysts

with commercially viable performance data expected in less than 12 months

Device shown is under development and subject to FDA clearance or approval

51 | PROPRIETARY AND CONFIDENTIAL PROPERTY OF ONE HEALTH BIOSENSING INC.

one health

one health

